Citius Pharmaceuticals
CTXR
60 hedge funds and large institutions have $14M invested in Citius Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 11 increasing their positions, 18 reducing their positions, and 29 closing their positions.
541% more call options, than puts
Call options by funds: $468K | Put options by funds: $73K
0.25% less ownership
Funds ownership: 0.66% → 0.42% (-0.25%)
21% less funds holding
Funds holding: 76 → 60 (-16)
39% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 18
48% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 29
68% less capital invested
Capital invested by funds: $43.2M → $14M (-$29.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.91M |
| 2 |
E
Ergoteles
New York
|
+$496K |
| 3 |
Renaissance Technologies
New York
|
+$374K |
| 4 |
Morgan Stanley
New York
|
+$177K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$136K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$6.29M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.78M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.06M |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$928K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$904K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIP
76
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$16K | -356 | Closed |
|
77
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$14K | -304 | Closed |
|
|
TRCT
78
Tower Research Capital (TRC)
New York
| – | -$12K | -267 | Closed |
|
|
SO
79
STRS Ohio
Columbus,
Ohio
| – | -$6K | -148 | Closed |
|
|
CPFP
80
Clear Perspectives Financial Planning
Cincinnati,
Ohio
| – | -$1K | -16 | Closed |
|
81
Rockefeller Capital Management
New York
| – | +$55 | +2 | New |
|
|
APC
82
Aspire Private Capital
Cornelius,
North Carolina
| – | +$329 | +12 | New |
|
CTXR Hedge Fund Activity: Q2 2022 in Review
60 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q2 2022, worth a combined $14M — down 68% from $43.2M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of CTXR and 15 opened new positions — a net loss of 14 holders — while 18 trimmed existing stakes and 11 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.91M. The largest seller was BlackRock, cutting an estimated $6.29M.
- 60 institutional investors held Citius Pharmaceuticals (CTXR) as of Q2 2022, down from 76 in Q1 2022.
- Funds reported $14M of Citius Pharmaceuticals stock for Q2 2022, down 68% quarter-over-quarter.
- 15 funds opened new Citius Pharmaceuticals positions in Q2 2022 and 29 closed out, a net change of -14 holders.
- The largest Citius Pharmaceuticals buyer in Q2 2022 was Millennium Management, an estimated $1.91M added.
- The largest Citius Pharmaceuticals seller in Q2 2022 was BlackRock, an estimated $6.29M sold.
Based on aggregated 13F filings for Q2 2022.